Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · see citing works

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379 · see citing works

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914 · see citing works

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665 · see citing works

Third generation EGFR TKIs: current data and future directions

Tan, C., Kumarakulasinghe, N. B., Huang, Y., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0778-0 · Cited by 317 · see citing works

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Ahn, M., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Sequist, L. V. D., Hida, T., Yang, J. C., Ramalingam, S. S., Mitsudomi, T., Janne, P. A., et al. (2018) · Cancer · doi:10.1002/cncr.31891 · Cited by 168 · see citing works

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

Takeda, M., Okamoto, I., Fujita, Y., Arao, T., Ito, H., Fukuoka, M., Nishio, K., & Nakagawa, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181cee47e · Cited by 76 · see citing works

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

Tan, D. S. W., Leighl, N. B., Riely, G. J., Yang, J. C., Sequist, L. V. D., Wolf, J., Seto, T., Felip, E., Ponce-Aix, S., Jonnaert, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30267-x · Cited by 75 · see citing works

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

Park, K., Lee, J.-S., Han, J. Y., Lee, K. H., Kim, J. H., Cho, E. K., Cho, J., Min, Y. J., Kim, J., & Kim, D.-W. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30243-x · Cited by 37 · see citing works

Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)

Tan, D. S. W., Kim, S.-W., Sequist, L. V. D., Ponce-Aix, S., Smit, E. F., Hida, T., Yang, J. C., Felip, E., Seto, T., Grohé, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.073 · Cited by 7 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Advances of Benzimidazole Derivatives as Anticancer Agents: Bench to Bedside

Haider, K., & Yar, M. S. (2022) · Biochemistry · doi:10.5772/intechopen.101702 · Cited by 30 · see citing works

Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study

Tan, D. S. W., Kim, S., Ponce-Aix, S., Sequist, L. V. D., Smit, E. F., Yang, J. C., Hida, T., Toyozawa, R., Felip, E., Wolf, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.023 · Cited by 19 · see citing works

Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

Hajjo, R., Sabbah, D. A., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327307 · Cited by 12 · see citing works

Bisulfite-Free and Quantitative Detection of DNA Methylation at Single-Base Resolution by eROS1-seq

Gang, F., Xie, N., Wang, M., Zhang, S., Ji, T., Liu, W., Guo, X., Gu, S.-Y., & Yuan, B. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05030 · Cited by 7 · see citing works

An afatinib-based theranostic fluorescent probe for cancer cells and its applications in monitoring pH changes during treatment

Wang, K., Wen, H., Liu, C., Li, Z., Wang, S., Zhu, H., Liu, M., Rong, X., Yu, M., Sheng, W., et al. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.137056 · Cited by 7 · see citing works

Circular RNA SPECC1 promoted tumorigenesis and osimertinib resistance in lung adenocarcinoma via a circular RNA-microRNA network

Hao, Z., Feng, F., Wang, Q., Wang, Y., Li, J., & Huang, J. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-2024-2144 · Cited by 7 · see citing works

Direct sequencing of DNA 5-methylcytosine by engineered dioxygenase NTET-assisted eNAPS

Zhang, S., Xie, N., Zeng, L., Gang, F., Gu, Y.-H., Wang, M., Guo, X., Ji, T., Xiong, J., & Yuan, B. (2025) · Chemical Science · doi:10.1039/d5sc03634h · Cited by 6 · see citing works

Precise Recognition and Quantification of Locus‐Specific DNA Methylation Using Engineered ROS1 †

Zeng, L., Gang, F., Ji, T., Zhang, S., Guo, X., Hao, Y., Xiong, J., Wei, Z., Xie, N., & Yuan, B. (2025) · Chinese Journal of Chemistry · doi:10.1002/cjoc.70044 · Cited by 4 · see citing works

Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

Felip, E., Metro, G., Soo, R. A., Wolf, J., Solomon, B., Tan, D. S. W., Ardizzoni, A., Lee, K. H., Sequist, L. V. D., Barlési, F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114182 · Cited by 3 · see citing works

Embryo-fetal developmental toxicity and toxicokinetics studies of YWS20045 orally administered to pregnant rats

Li, H., Peng, Y., Shao, Q., & Qiao, H. (2025) · Toxicology Letters · doi:10.1016/j.toxlet.2025.111749 · Cited by 1 · see citing works

Small-molecule kinase-targeted covalent inhibitors till 2025: A comprehensive review of discovery, binding modes, clinical indications, and synthetic approaches

Dahab, M. A., Ashoub, A. F., Ali, R. A., Sallam, A. S., & Mayhoub, A. S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119449

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

Tan, D. S. W., Leighl, N. B., Riely, G. J., Yang, J. C., Sequist, L. V. D., Wolf, J., Seto, T., Felip, E., Ponce-Aix, S., Jonnaert, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30267-x · Cited by 75 · see citing works

Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer

Cui, J., Xiao, Z., & Zhang, L. (2021) · Medicine · doi:10.1097/md.0000000000025992 · Cited by 6 · see citing works

Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study

Tan, D. S. W., Kim, S., Ponce-Aix, S., Sequist, L. V. D., Smit, E. F., Yang, J. C., Hida, T., Toyozawa, R., Felip, E., Wolf, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.023 · Cited by 19 · see citing works

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

Kim, D., Tan, D. S.-W., Ponce-Aix, S., Sequist, L. V. D., Smit, E. F., Hida, T., Yang, J. C., Felip, E., Seto, T., Grohé, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9094 · Cited by 16 · see citing works

1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer

Felip, E., Minotti, V., Soo, R. A., Wolf, J., Solomon, B., Tan, D. S.-W., Ardizzoni, A., Lee, D. H., Sequist, L. V. D., Barlési, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1598 · Cited by 8 · see citing works